We claim:

1. A tetanus toxin protein variant, comprising the segment C of the tetanus toxin protein and the partial segment of the translocation region of the tetanus toxin protein.
2. The tetanus toxin protein variant according to claim 1, wherein the partial segment of the translocation region comprises the T cell epitope P2 of the translocation region of the tetanus toxin protein.
3. The tetanus toxin protein variant according to claim 1, wherein the partial segment of the translocation region comprises amino acids 829-864 of the tetanus toxin protein.
4. The tetanus toxin protein variant according to claim 1, wherein the partial segment of the translocation region comprises the amino acid sequence shown in any one of SEQ ID NO: 7-8.
5. The tetanus toxin protein variant according to claim 1, wherein the segment C of the tetanus toxin protein comprises the amino acid sequence shown in SEQ ID NO:3.
6. The tetanus toxin protein variant according to claim 1, comprising the amino acid sequence shown in any one of SEQ ID NO: 1-2.
7. A polysaccharide protein conjugate comprising a polysaccharide from Streptococcus pneumoniae and a truncated tetanus toxin protein.
8. The polysaccharide protein conjugate according to claim 7, wherein the polysaccharide is selected from any one or more serotype of the group of Streptococcus pneumoniae serotype consisting of: 1, 2, 3, 4, 5, 6A , 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F.
9. The polysaccharide protein conjugate according to claim 7, wherein the truncated tetanus toxin protein comprises a segment C of the tetanus toxin protein, or comprises a segment C of the tetanus toxin protein and a partial segment of the translocation region of the tetanus toxin protein.
10. The polysaccharide protein conjugate according to claim 7, wherein the segment C of the tetanus toxin protein comprises the amino acid sequence shown in SEQ ID NO:3.
11. The polysaccharide protein conjugate according to claim 7, wherein the truncated

tetanus toxin protein comprises the amino acid sequence shown in SEQ ID NO:1-3.

12. The polysaccharide protein conjugate according to claim 7, wherein the mass ratio of the polysaccharide to the truncated tetanus toxin protein is 0.4-2.5.

13. A method for improving immunogenicity, comprising the step of: providing a polysaccharide protein conjugate according to any one of claims 7-12.

14. A nucleic acid molecule, comprising a sequence encoding the tetanus toxin protein variant of any one of claims 1-6.

15. A vector, comprising the nucleic acid molecule of claim 14.

16. A cell, comprising the nucleic acid molecule of claim 14 or the vector of claim 15.

17. A pharmaceutical composition, comprising the polysaccharide protein conjugate of any one of claims 7-12 and optionally a pharmaceutically acceptable adjuvant.

18. A vaccine, comprising the polysaccharide protein conjugate of any one of claims 7-12, the pharmaceutical composition of claim 17 and optionally a pharmaceutically acceptable adjuvant.

19. The polysaccharide protein conjugate of any one of claims 7-12, the nucleic acid molecule of claim 14, the vector of claim 15, the cell of claim 16, the pharmaceutical composition of claim 17 and/or the vaccine of claim 18 for use in the prevention of disease caused by Streptococcus pneumoniae infection in a subject.

20. Use of the polysaccharide protein conjugate of any one of claims 7-12, the nucleic acid molecule of claim 14, the vector of claim 15, the cell of claim 16, the pharmaceutical composition of claim 17 and/or the vaccine of claim 18 in the manufacture of a medicament for the prevention of disease caused by Streptococcus pneumoniae infection in a subject.

21. A kit, comprising the polysaccharide protein conjugate of any one of claims 7-11.